Patient and caregiver discussing transplant testing with a provider

A better transplant testing journey for patients & providers

From pre-transplant to matching and post-transplant testing, expedited turnaround times and dedicated support are essential to providing exceptional transplant experiences and outcomes for patients, donors, and their medical care team. As a leader in healthcare diagnostics, Quest Diagnostics is uniquely qualified to help with our comprehensive menu of HLA typing and infectious disease testing, expedited transport and processing, and support for patients and caregivers during their critical window of opportunity. And our medical team of 600+ MDs and PhDs stands ready to provide caregivers with esoteric consultation.1

Offer the best experience at every step

Explore our transplant tests

With one of the most comprehensive transplant testing portfolios available today, Quest Diagnostics Specialized Transplant Services is here to help support testing needs across the transplant journey

View tests

Achieve better outcomes with meaningful support throughout the entire transplant experience

No other commercial lab offers the Quest combination of expedited turnaround times and broad testing portfolio, or our specialized level of service for advanced infectious disease transplant testing, to help improve outcomes.

Explore the latest in transplant testing and services

We’re eager to share what we’ve done to improve transplant experiences and outcomes.

Let’s talk

Discover our new CMV genotypic resistance testing

Ensure better outcomes with our new cytomegalovirus (CMV) genotypic resistance testing. This advanced test offers precise detection, rapid results, and supports tailored antiviral therapies for transplant patients.

View our tests

What's New?

Now introducing APOL1

Quest Diagnostics now offers Apolipoprotein L1 Renal Risk Variant Genotyping (APOL1). The APOL1 test confirms the presence of 2 apolipoprotein L1 gene risk variants, providing insight into a potential donor’s risk of developing chronic kidney disease (CKD). To learn more about how APOL1 insights can help overcome previous barriers for higher-risk donors, speak with a Quest representative.

Contact a representative